This announcement is a separate document:
國藥控股：(1)持續關連交易：二零二三年採購框架協議及二零二三年銷售框架協議； (2)須予披露交易及持續關連交易：二零二三年金融服務框架協議； (3)建議修改公司章程；及 (4)股東特別大會通告
SINOPHARM: (1) CONTINUING CONNECTED TRANSACTIONS: 2023 PROCUREMENT FRAMEWORK AGREEMENT AND 2023 SALES FRAMEWORK AGREEMENT; (2) DISCLOSEABLE TRANSACTION AND CONTINUING CONNECTED TRANSACTION: 2023 FINANCIAL SERVICES FRAMEWORK AGREEMENT; (3) PROPOSED AMENDMEN
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.